Glaukos (GKOS) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 28, 2026, with voting on director elections, executive compensation, and auditor ratification.

• Company achieved 32% net sales growth in 2025, with $507M in net sales and $283M in cash and equivalents at year-end.

• Major product launches included iDose TR and Epioxa, with strong adoption and expanded market access.

• Sustainability initiatives advanced, including climate risk assessment, sustainable packaging, and expanded patient access programs.

Voting matters and shareholder proposals

• Shareholders to vote on electing two Class II directors (Denice M. Torres and Aimee S. Weisner) for terms expiring in 2029.

• Advisory vote on executive compensation (say-on-pay) and ratification of Ernst & Young LLP as independent auditor for 2026.

• Board recommends voting FOR all proposals.

Board of directors and corporate governance

• Board consists of eight directors, seven of whom are independent; CEO is not independent.

• Board committees: Audit and Compensation, Nominating & Governance (CNG), both fully independent.

• Lead Independent Director role established; regular board and committee self-evaluations and peer reviews.

• Board diversity: 38% women, 25% from underrepresented communities, average age 61.

• Overboarding policy limits directors to four public boards (two if an active CEO).